TO 36 U.S. PTO 09/950024

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of) Prior Group Art Unit: 163	1
Hua Zhu, et al.) Prior Examiner: Y. Kim	
Continuation of)	
Serial No. 09/377,907)	
Filed: September 12, 2001) Atty. Dkt. No. 03848.0009) 6

For: Expression Monitoring For Human Cytomegalovirus (HCMV) Infection

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner of Patents Washington, D.C. 20231

Sir:

Pursuant to the duty of good faith and candor as set forth in 37 C.F.R. § 1.56(a) Applicant submits herewith a Form PTO 1449. Since these documents were previously cited in Application Serial No. 09/377,907 no copies are being supplied herewith.

Applicant respectfully requests that the Examiner consider and enter these documents into the file of the above-identified application. No fee is believed to be due to ensure consideration and entry of the cited documents by the Examiner. However, if a fee is deemed necessary, the Commissioner is authorized to charge our Deposit Account No. 19-0733.

Respectfully submitted,

Sarah A. Kagan

Registration No. 32,141

Dated: September 12, 2001

BANNER & WITCOFF, LTD. 1001 G Street, N.W., 11th Floor Washington, D.C. 20001

TEL: (202) 508-9100 FAX: (202) 508-9299

	Sheet _1_ of _1_	р =
ATTY. DOCKET NO. 03849,00096	serial number TBA/Cont. 09/377.907	124 124 01
APPLICANT Hau Zhu et al.		36 U.S 39/9500
FILING DATE September 12, 2001	group art unit 1631	17.0

PTO-1449 (Modified)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE
	5,561,071	10/1/1996	Hollenberg et al.			
	5,733,729	03/31/1998	Lipshutz et al.			
	5,795,716	08/18/98	Chee et al.			

FOREIGN PATENT DOCUMENTS


EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION YES/NO
	_					

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

-	Shibutani et al. "Pertussis Toxin-sensitive G Proteins as Mediators of the Signal Transduction Pathways Activated by Cytomegalovirus Infection of Smooth Muscle Cells" The Journal of Clinical Investigation, Volume 100, Number 8, October 1997 pages 2054-2061
i	Zhu et al. "Cellular gene expression altered by human cytomegalovirus: Global monitoring with oligonucleotide arrays" Proc. Natl. Acad. Sci. USA Vol. 95 pages 14470-14475, November 1998
	Geist and Dai "Cytomegalovirus Modulates Interleukin-6 Gene Expression" Transplantation, Vol. 62, No. 5, September 1996, pages 653-658
	Zhou et al. "Human Cytomegalovirus Increases Modified Low Density Lipoprotein Uptake and Scavenger Receptor mRNA Expression in Vascular Smooth Muscle Cells" The Journal of Clinical Investigation, Vol. 98, No. 9, November 1996, pages 2129-2138
	J. Zhu "Ultraviolet B irradiation and cytomegalovirus infection synergize to induce the cell surface expression of 52-kD/Ro antigen" Clin Exp. Immunol. 1996: 103:47-53
	Boldogh et al. "Novel Activation of γ-Interferon in Nonimmune Cells during Human Cytomegalovirus Replication" Proceedings of the Society for Experimental Biology and Medicine, Vol. 215, No. 1, May 1997
	Lois J. Geist et al. "The Immediate Early Genes of Human Cytomegalovirus Upregulate Tumor Necrosis Factor-α Gene Expression" J. Clin. Invest. Vol. 93, February 1994, pages 474-478
	Colberg-Poley and Santomenna "Selective Induction of Chromosomal Gene Expression by Human Cytomegalovirus" Virology, 1988, Vol. 166, pages 217-228
	Zhu et al. "Use of Differential Display and DNA Array Technology to Assess the Effect of Human Cytomegalovirus Infection on Signal Transeduction pathways. FASEB Journal, April 1998, Vol. 12, No. 8, page A1308

EXAMINER		DATE CONSIDERED				

EXAMINER: Initial citation if reference was considered. Draw line through citation if not in conformance to MPEP 609 and not considered. Include copy of this form with next communication to applicant.



Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Substitute for form 1449A/PTO Complete if Known

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application Number TBA/Continuation of 09/377,907 Filing Date September 12, 2001 First Named Inventor Hua Zhu et al. **Prior Group Art Unit** 1631 **Prior** Examiner Name Y. Kim

(use as many sheets as necessary)

Sheet Attorney Docket Number 03848.00096

U.S. PATENT DOCUMENTS							
Examiner Cite U.S. Patent Document		Name of Patentee or Applicant	Date of Dublication of	Barre Calarra Line Miles Balance			
Cite No. ¹	l Number		of Cited Document	Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
	5,700,637		Southern	12/23/97			
	6,124,433		Falb et al	09/26/00			
	-						
	Cite No.1	Cite No.1 Number Kind C (if kno) 5,700,637	Cite Number Kind Code ² (if known)	Cite No.1	U.S. Patent Document Name of Patentee or Applicant Date of Publication of Cited Document MM-DD-YYYY		

				FOREIG	N PATENT DOCU	IMENTS		
Examiner Cite	Cite	Foreign Patent Document			Name of Patentee	Date of Publication of	Pages, Columns, Lines, Where Relevant	
Initials*	No.1	Office ³	Number ⁴	Kind Code ⁵ (if known)	or Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	T ₆
		WIPO	89/10977			11/16/89		
		ОТ	HER PRIO	R ART N	ON PATENT LITE	RATURE DOCUME	ENTS	,
Examiner Initials *	Cite No.1		n (book, mag	ame of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				T²
				ogen genomes 1996, pages 29		ntifying therapeutics and v	vaccine targets", Trends in	
		Shiue L, "Identification of candidate genes for drug discovery by differential display", Drug Development Research, Vol.41, Jul-Aug 1997, pages 142-159.						
		Maier E et al, "Automated array technologies for gene expression profiling", Drug Discovery Today, Vol. 2, No. 8, August 1997, pages 315-324.						
		Bertelsen	AH et al, "High	-throughput ge	ene expression analysis April 1998, pages		covery Today, Vol. 3, No. 4,	

Examiner Signature	Date Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark hee if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.